T11328 |
FT-1518 |
FT-1518 ,exhibits antitumor activity, is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor. |
T11742L |
K-7174 dihydrochloride |
K-7174 dihydrochloride is a novel cell adhesion inhibitor; inhibits the expression of vascular cell adhesion molecule-1 (VCAM-1) induced by either IL-1β or TNF...
|
T12123 |
mTOR inhibitor-3 |
mTOR inhibitor-3 is an inhibitor of remarkably selective mTOR (Ki : 1.5 nM) |
T12124 |
mTOR inhibitor-2 |
mTOR inhibitor-2 is an inhibitor of selective and oral mTOR (IC50 of 7 nM). |
T12270 |
NV-5138 |
NV-5138 is a selective and orally active activator of brain mTORC1, with antidepressant effects. |
T14033 |
3BDO |
3BDO is an activator of mTOR. It can also inhibit autophagy.. |
T14552 |
Dactolisib Tosylate |
Dactolisib Tosylate (BEZ235 Tosylate) is an inhibitor of dual PI3K and mTOR kinase(IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively). Dactolis...
|
T1537 |
RapamycinHOT |
Rapamycin, a macrolide compound obtained from Streptomyces hygroscopicus, is a potent and specific mTOR inhibitor (IC50: 0.1 nM in HEK293 cells). |
T16263 |
N6-Cyclopentyladenosine |
N6-Cyclopentyladenosine (CPA) is a selective agonist of Adenosine A1 receptor (Ki: 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively). |
T1784 |
EverolimusHOT |
Everolimus is a potent mTOR inhibitor that binds to FKBP-12. It is used alone or in combination with calcineurin inhibitors. |
T1838 |
INK 128 |
INK 128 is an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activ...
|
T1859 |
AZD8055HOT |
AZD8055 is an ATP-competitive mTOR inhibitor (IC50: 0.8 nM in MDA-MB-468 cells). It is ~1,000-fold selective for mTOR over all PI3K isoforms. |
T1861 |
Omipalisib |
GSK2126458 is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. |
T1908 |
MHY1485 |
MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3...
|
T1916 |
Apitolisib |
Apitolisib, an effective, class I PI3K inhibitor for PI3Kα(IC50=5 nM), PI3Kβ(IC50=27 nM), PI3Kδ(IC50=7 nM), PI3Kγ (IC50=14 nM), is used in t...
|
T1920 |
CapivasertibHOT |
Capivasertib (AZD5363) is a new-type orally available inhibitor of the serine/threonine protein kinase AKT (IC50s: 3/7/7 nM for Akt1/2/3). |
T1958 |
AZ20 |
AZ20 is an effective and specific inhibitor of ATR kinase (IC50: 5 nM, in a cell-free assay), 8-fold selectivity over mTOR. |
T1961 |
Vistusertib |
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. |
T1970 |
Gedatolisib |
Gedatolisib is a highly effective dual inhibitor targeting the PI3Kα/γ (IC50: 0.4/5.4 nM)and mTOR (IC50: 1.6 nM) in the PI3K/mTOR signaling pathway. |
T2083 |
PI3065 |
PI-3065 is a novel potent and selective PI3K p110δ inhibitor. |
T2084 |
ETP46464 |
ETP-46464 is an effective and specific ATR inhibitor (IC50: 25 nM). |
T2144 |
TacrolimusHOT |
Tacrolimus can bind FKBP12 to form a high-affinity complex (Ki: 0.2 nM) which inhibits the activity of the calcium/calmodulin-dependent protein phosphatase. |
T2145 |
TemsirolimusHOT |
Temsirolimus is a specific mTOR inhibitor ( IC50: 1.76 μM), used in the treatment of advanced renal cell cancer. |
T2235 |
DactolisibHOT |
Dactolisib is an orally bioavailable inhibitor of PI3K and mTOR (IC50s: 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR). |
T2265 |
PI3K-IN-2 |
PI3K-IN-2 is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase ...
|
T2357 |
GSK-1059615 |
GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer. |
T2414 |
TorkinibHOT |
Torkinib (PP 242) is a selective and ATP-competitive mTOR inhibitor (IC50: 8 nM). It also inhibits mTORC1/2 (IC50s: 30/58 nM). |
T2415 |
PP121 |
PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) ,...
|
T2434 |
LY 303511 |
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor and no inhibition for PI3-K. |
T2475 |
KU0063794 |
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2. |
T2616 |
PIK-93 |
PIK-93 is the first potent, synthetic PI4K inhibitor with IC50 of 19 nM; inhibits PI3Kα with IC50 of 39 nM. |
T2619 |
CH5132799 |
CH5132799 has been used in trials studying the treatment of Solid Tumors. |
T2685 |
KU55933 |
KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor. |
T2706 |
Palomid 529 |
Palomid 529 has been used in trials studying the treatment of Age-Related Macular Degeneration. |
T2998 |
Dihydromyricetin |
Dihydromyricetin is a natural antioxidant flavonoid from Ampelopsis grossedentata. Dihydromyricetin is a potent inhibitor of dihydropyrimidinase with an IC50 of...
|
T2S1040 |
Jolkinolide B |
Jolkinolide B has potent anti-inflammatory, and antitumor activities, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part,...
|
T3153 |
Serabelisib |
MLN1117 (INK1117) is a p110α/β/γ/δ inhibitor (IC50: 15/4.5/1.9/13.39μM). |
T3351 |
CC-223 |
CC-223 is an orally available mTOR inhibitor with potential antitumor activity. CC-223 inhibits the activity of mTOR, which may result in the induction of tumor...
|
T3395 |
Timosaponin AIII |
Timosaponin AIII induces autophagy in HeLa cells followed by apoptotic cell death (IC50: 10μM). The Timosaponin AIII cellular response is mediated via inhibiti...
|
T3514 |
CZ415 |
CZ415 is a potent and highly selective mTOR inhibitor. |
T3541 |
CC-115 |
CC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM). |
T3692 |
GNE 477 |
GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor. |
T3705 |
GDC-0084 |
GDC-0084 (RG7666) is a PI3K inhibitor with potential antineoplastic activity. GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) s...
|
T3851 |
Vicenin -2 |
Vicenin -2 has hepatoprotective, anti-cancer, antioxidant and anti-inflammatory activities, and DTL co-administration is more effective than either of the singl...
|
T3986 |
SF2523 |
SF2523 is a highly selective and potent inhibitor. |
T3S0209 |
Vincristine |
Vincristine-induced nociceptive painful sensation, may be due to its potential of antioxidative, neuroprotective and calcium channel inhibitory action.Vincristi...
|
T4199 |
Desmethyl-VS-5584 |
Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. |
T4423 |
LY303511 hydrochloride |
LY303511 (NV-128)is a potent mTOR inhibitor |
T4488 |
GSK-25 |
GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC50 of 398 nM, p70S6K IC50 of 1000nM), and a dramatically imp...
|
T4639 |
MSDC 0602 |
MSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes. |
T5338 |
mTOR inhibitor-1 |
C-4 is a potential ATP-competitive inhibitor of mTOR. C-4 could inhibit cell growth and proliferation. |
T5472 |
PQR620 |
PQR620 is a novel potent and selective, brain penetrant inhibitor of mTORC1/2. |
T6030 |
XL388 |
XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases. |
T6033 |
Zotarolimus |
Zotarolimus, an analogue of rapamycin, inhibits FKBP-12 (IC50= 2.8 nM). |
T6045 |
Torin 1 |
Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold selectivity for mTOR than PI3K. |
T6100 |
Torin 2 |
Torin 2(IC50=0.25 nM), a specific and effective mTOR inhibitor, is the 800-fold greater specific activity for mTOR than PI3K and improves pharmacokinetic proper...
|
T6103 |
VS-5584 |
VS-5584 is a pan-PI3K/mTOR kinase inhibitor. |
T6143 |
PI-103HOT |
PI-103 is a potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50s: 2/3/3/15/30/23 nM for p110α/β/δ/γ, mTOR, and DNA-PK). |
T6319 |
OSI-027 |
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI...
|
T6334 |
Ridaforolimus |
Ridaforolimus is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus bin...
|
T6510 |
GDC-0349 |
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1...
|
T6731 |
WYE-354 |
WYE-354(IC50=5 nM) is an effective, selective and ATP-competitive mTOR inhibitor. It blocks mTORC2/P-AKT(S473) and mTORC1/P-S6K(T389), not P-AKT(T308). The sele...
|
T6732 |
WYE-687 |
WYE-687 is an ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM; blocks mTORC1/pS6K(T389) and mTORC2/P-AKT(S473) but no effect observed on P-AKT...
|
T6883 |
LY3023414 |
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. LY3023414 has been used in trials studying the treatment of Neopl...
|
T7166 |
GNE-493 |
GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for...
|
T8569 |
DMH-25 |
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells. |
T8649 |
TMBIM6 antagonist-1 |
TMBIM6 antagonist-1 is an antagonist of TMBIM6. |
TMA0507 |
Tomatidine |
Tomatidine shows antibiotic, and anti-inflammatory activities, it significantly suppresses the activity of ACAT and leads to reduction of atherogenesis. Tomatid...
|
TN1140 |
Onjisaponin B |
Onjisaponin B induces autophagy via the AMPK-mTOR signaling pathway, increases the NGF level and accelerates both the removal of mutant huntingtin and A53T α±...
|
TN1245 |
3-Deoxysappanchalcone |
3-Deoxysappanchalcone is an effective HO-1 inducer at the translational level. |
TN2118 |
Pulsatilla saponin D |
Pulsatilla saponin D exhibits anticancer activities in various cancer types, it Inhibits autophagic flux and synergistically enhances the anticancer activity of...
|
TN2250 |
Syringaresinol |
(-)-Syringaresinol may be a potential chemotherapeutic agent for the treatment of cancer; it against H/R-induced cardiomyocyte injury and death, the degradation...
|
TN2328 |
Zeylenone |
Zeylenone has good antitumor efficacy, it inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. Zeyl...
|
TN3218 |
7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one |
7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one as a beneficial compound to ameliorate the deleterious effects of Aβ on dendrite integrity and cell survival, and m...
|
TN3310 |
9,9'-Di-O-(E)-feruloylsecoisolariciresinol |
1,4-O-Diferuloylsecoisolariciresinol(9,9'-Di-O-(E)-feruloylsecoisolariciresinol),and pierreione B, two novel inhibitors of mTOR signaling, have strong anticance...
|
TN4213 |
Hirsutenone |
Hirsutenone has potent antioxidant activity, it shows significant free radical scavenging activity and exhibits inhibition effect on the mitochondrial lipid per...
|
TN4356 |
Jolkinolide A |
Jolkinolide A has anti-tumor activity. It inhibited VEGF expression in A549 cells through the inhibition of the Akt-STAT3-mTOR signaling pathway, and directly i...
|
TN4382 |
Kazinol A |
Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6-164 M a...
|
TN4788 |
Pierreione B |
Pierreione B is an inhibitor of mTOR signaling with strong anticancer activity. Pierreione A and Pierreione B demonstrate solid tumor selectivity with minimal c...
|
TN5050 |
Sprengerinin C |
Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can s...
|